Fox Christine's Form 4 filing
Teva Pharmaceutical Industries Ltd (TEVA) · filed Nov 18, 2025
- Accession no.
- 0001193125-25-286134
- Filed
- Nov 18, 2025
- Trade date
- Nov 14, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $753.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fox ChristineCIK 0001998173 | Officer (EVP, Head of U.S. Commercial) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2025 | Ordinary Shares | SSaleDisposed | −30,000 | $25.11 | −$753,300 | 28,384 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.